4.5 Article

Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial

期刊

CLINICAL AND EXPERIMENTAL ALLERGY
卷 40, 期 5, 页码 795-804

出版社

WILEY
DOI: 10.1111/j.1365-2222.2010.03465.x

关键词

atopic dermatitis; infant; prebiotics; probiotics; synbiotics

资金

  1. Danone Research - Centre for Specialised Nutrition

向作者/读者索取更多资源

P>Background Clinical trials investigating the therapeutic effect of probiotics on atopic dermatitis (AD) show inconsistent results. Better results can possibly be achieved by combining probiotics with prebiotics, i.e. synbiotics. Objective To investigate the therapeutic effect of a synbiotic mixture on the severity of AD in infants. Methods In a double-blind, placebo-controlled multi-centre trial, 90 infants with AD [SCORing Atopic Dermatitis (SCORAD) score >= 15], aged < 7 months and exclusively formula fed, were randomly assigned to receive either an extensively hydrolysed formula with Bifidobacterium breve M-16V and a galacto-/fructooligosaccharide mixture (Immunofortis (R)), or the same formula without synbiotics for 12 weeks. The primary outcome was severity of AD, assessed using the SCORAD index. A secondary outcome measure was intestinal microbiota composition. Results There was no difference in SCORAD score improvement between the synbiotic and the placebo group. The synbiotic group did have a significantly higher percentage of bifidobacteria (54.7% vs. 30.1%, P < 0.001) and significantly lower percentages of Clostridium lituseburense/Clostridium histolyticum (0.5 vs. 1.8, P=0.02) and Eubacterium rectale/Clostridium coccoides (7.5 vs. 38.1, P < 0.001) after intervention than the placebo group. In the subgroup of infants with IgE-associated AD (n=48), SCORAD score improvement was significantly greater in the synbiotic than in the placebo group at week 12 (-18.1 vs. -13.5 points, P=0.04). Conclusions This synbiotic mixture does not have a beneficial effect on AD severity in infants, although it does successfully modulate their intestinal microbiota. Further randomized-controlled trials should explore a possible beneficial effect in IgE-associated AD. Cite this as: L. B. van der Aa, H. S. Heymans, W. M. van Aalderen, J. H. Sillevis Smitt, J. Knol, K. Ben Amor, D. A. Goossens, A. B. Sprikkelman and the Synbad Study Group, Clinical & Experimental Allergy, 2010 (40) 795-804.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据